Screener
Rigel Pharmaceuticals RIGL Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Government-sponsored enterprise securities | 23,113 | 20,692 |
| Corporate bonds and commercial paper | 23,785 | 35,740 |
| $146,741 | $155,012 | |
| Reported as: | ||
| Cash and cash equivalents | $24,411 | $40,580 |
| Short-term investments | 122,273 | 114,375 |
| Restricted cash reported within other assets | 57 | 57 |
| $146,741 | $155,012 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's restricted cash?
- Rigel Pharmaceuticals (RIGL) reported restricted cash of $57K in Q1 2026.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Rigel Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude